Qulipta, a medication for episodic migraine, is not currently available as a generic. The drug's manufacturer, AbbVie, holds patents that protect its market exclusivity.
When Does Qulipta's Patent Protection End?
The exact expiration dates for Qulipta's patents are not publicly disclosed in full detail. However, patent information for pharmaceuticals, including Qulipta, can be tracked through resources like DrugPatentWatch.com [1]. Patent expiry dates are crucial for determining when generic versions of a drug can enter the market.
What is Qulipta and How Does It Work?
Qulipta (atogepant) is an oral calcitonin gene-related peptide (CGRP) receptor antagonist. It is prescribed for the preventive treatment of episodic migraine in adults [2]. CGRP is a neuropeptide implicated in migraine pathophysiology, and by blocking its receptor, Qulipta aims to reduce migraine frequency [2].
Who Makes Qulipta?
AbbVie, a global biopharmaceutical company, manufactures and markets Qulipta. The drug was developed by Allergan, which was acquired by AbbVie in 2020 [3].
What Are the Next Steps for Generic Qulipta?
The development of generic medications typically begins once the innovator drug's patents are nearing expiration. Generic manufacturers will then file applications with regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to seek approval for their versions. This process involves demonstrating that the generic drug is bioequivalent to the brand-name drug. The availability of generic Qulipta will depend on the successful navigation of the patent landscape and regulatory approval processes.
How Does Qulipta Compare to Other Migraine Preventive Treatments?
Qulipta is part of a class of drugs targeting the CGRP pathway, which also includes injectable CGRP monoclonal antibodies like Aimovig, Ajovy, and Emgality, as well as other oral CGRP antagonists. These treatments offer different administration routes and may have varying efficacy and side effect profiles. Preventive medications for migraine also include older drug classes such as beta-blockers, anticonvulsants, and antidepressants, which work through different mechanisms.
What Are the Risks of Taking Qulipta?
Common side effects of Qulipta include nausea, constipation, and fatigue [2]. Patients should discuss potential risks and benefits with their healthcare provider.
Sources:
[1] https://drugpatentwatch.com/
[2] Qulipta Prescribing Information
[3] AbbVie Inc. Investor Relations